Introduction: The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study. Materials and methods: The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models. Results: Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42–65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22–25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles. Conclusions: Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years.

Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study / Hompland I.; Ferrari S.; Bielack S.; Palmerini E.; Hall K.S.; Picci P.; Hecker-Nolting S.; Donati D.M.; Blattmann C.; Bjerkehagen B.; Staals E.; Kager L.; Gambarotti M.; Kuhne T.; Eriksson M.; Ferraresi V.; Kevric M.; Biagini R.; Baumhoer D.; Brosjo O.; Comandone A.; Schwarz R.; Bertulli R.; Kessler T.; Hansson L.; Apice G.; Heydrich B.-N.; Setola E.; Florcken A.; Ruggieri P.; Krasniqi F.; Hofmann-Wackersreuther G.; Casali P.; Reichardt P.; Smeland S.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 151:(2021), pp. 150-158. [10.1016/j.ejca.2021.04.017]

Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study

Palmerini E.;Donati D. M.;Staals E.;Biagini R.;Setola E.;
2021

Abstract

Introduction: The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study. Materials and methods: The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models. Results: Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42–65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22–25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles. Conclusions: Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years.
2021
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study / Hompland I.; Ferrari S.; Bielack S.; Palmerini E.; Hall K.S.; Picci P.; Hecker-Nolting S.; Donati D.M.; Blattmann C.; Bjerkehagen B.; Staals E.; Kager L.; Gambarotti M.; Kuhne T.; Eriksson M.; Ferraresi V.; Kevric M.; Biagini R.; Baumhoer D.; Brosjo O.; Comandone A.; Schwarz R.; Bertulli R.; Kessler T.; Hansson L.; Apice G.; Heydrich B.-N.; Setola E.; Florcken A.; Ruggieri P.; Krasniqi F.; Hofmann-Wackersreuther G.; Casali P.; Reichardt P.; Smeland S.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 151:(2021), pp. 150-158. [10.1016/j.ejca.2021.04.017]
Hompland I.; Ferrari S.; Bielack S.; Palmerini E.; Hall K.S.; Picci P.; Hecker-Nolting S.; Donati D.M.; Blattmann C.; Bjerkehagen B.; Staals E.; Kager L.; Gambarotti M.; Kuhne T.; Eriksson M.; Ferraresi V.; Kevric M.; Biagini R.; Baumhoer D.; Brosjo O.; Comandone A.; Schwarz R.; Bertulli R.; Kessler T.; Hansson L.; Apice G.; Heydrich B.-N.; Setola E.; Florcken A.; Ruggieri P.; Krasniqi F.; Hofmann-Wackersreuther G.; Casali P.; Reichardt P.; Smeland S.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0959804921002483-main.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 767.21 kB
Formato Adobe PDF
767.21 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/831005
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 17
social impact